Simon Quick Advisors LLC Has $685,000 Stock Holdings in Bristol Myers Squibb Company $BMY

Simon Quick Advisors LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 19.8% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,788 shares of the biopharmaceutical company’s stock after buying an additional 2,440 shares during the quarter. Simon Quick Advisors LLC’s holdings in Bristol Myers Squibb were worth $685,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BMY. New England Asset Management Inc. lifted its stake in shares of Bristol Myers Squibb by 0.8% in the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company’s stock valued at $2,408,000 after purchasing an additional 305 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of Bristol Myers Squibb by 1.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company’s stock valued at $78,580,000 after purchasing an additional 13,959 shares during the period. Sage Capital Advisors llc lifted its stake in shares of Bristol Myers Squibb by 60.7% in the 2nd quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company’s stock valued at $3,946,000 after purchasing an additional 32,181 shares during the period. Ransom Advisory Ltd acquired a new position in shares of Bristol Myers Squibb in the 1st quarter valued at $843,000. Finally, Castle Rock Wealth Management LLC lifted its stake in shares of Bristol Myers Squibb by 458.2% in the 2nd quarter. Castle Rock Wealth Management LLC now owns 44,559 shares of the biopharmaceutical company’s stock valued at $2,088,000 after purchasing an additional 36,576 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Price Performance

BMY stock opened at $46.10 on Friday. The stock has a 50-day moving average price of $45.34 and a two-hundred day moving average price of $46.82. The stock has a market cap of $93.82 billion, a PE ratio of 18.59, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio is currently 100.00%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BMY. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a research report on Thursday, October 2nd. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research report on Tuesday, August 5th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $57.23.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.